These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3407585)

  • 1. Family abuse of methylphenidate.
    Fulton AI; Yates WR
    Am Fam Physician; 1988 Aug; 38(2):143-5. PubMed ID: 3407585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A drug to ease attention deficit-hyperactivity disorder.
    Smitherman CH
    MCN Am J Matern Child Nurs; 1990; 15(6):362-5. PubMed ID: 2124318
    [No Abstract]   [Full Text] [Related]  

  • 3. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult].
    Durst R; Rebaudengo-Rosca P
    Harefuah; 1997 May; 132(9):618-22, 680. PubMed ID: 9225572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Student perceptions of methylphenidate abuse at a public liberal arts college.
    Babcock Q; Byrne T
    J Am Coll Health; 2000 Nov; 49(3):143-5. PubMed ID: 11125642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.
    Fogelman Y; Kahan E
    Isr Med Assoc J; 2001 Dec; 3(12):925-7. PubMed ID: 11794916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substance abuse in adolescents: diagnostic issues derived from studies of attention deficit disorder with hyperactivity.
    Loney J
    NIDA Res Monogr; 1988; 77():19-26. PubMed ID: 3145426
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder].
    Kiliç BG; Bilgiç A; Gürkan K; Aysev A
    Turk Psikiyatri Derg; 2007; 18(3):207-13. PubMed ID: 17853975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate abuse in Texas, 1998-2004.
    Forrester MB
    J Toxicol Environ Health A; 2006 Jun; 69(12):1145-53. PubMed ID: 16728377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use.
    Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():4-8. PubMed ID: 18307375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review.
    Schubiner H; Tzelepis A; Isaacson JH; Warbasse LH; Zacharek M; Musial J
    J Clin Psychiatry; 1995 Apr; 56(4):146-50. PubMed ID: 7713853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
    J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse.
    Kuczenski R; Segal DS
    Biol Psychiatry; 2005 Jun; 57(11):1391-6. PubMed ID: 15950013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.